493 related articles for article (PubMed ID: 25579119)
1. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
2. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
5. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
6. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
8. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
9. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
10. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
11. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
12. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
13. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
14. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
15. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
16. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
18. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
Xu ZH; Yao TZ; Liu W
Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
20. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
